- |||||||||| EPC-002 / Elpis Biopharma
Journal: Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates. (Pubmed Central) - Jun 14, 2023
The in vitro mycobacterial growth inhibition assay demonstrated that EPCP009m inhibited Mycobacterium tuberculosis (Mtb) growth most strongly, followed by EPCP009f, which was significantly better than that of the other four vaccine candidates. These results indicated that EPCP009m containing four immunodominant antigens exhibited better immunogenicity and Mtb growth inhibition in vitro and may be a promising candidate vaccine for the control of TB.
- |||||||||| EPB-001 / Elpis Biopharma, Luye Group, EPIM-001 / Elpis Biopharma
Enhancing Anti-Tumor Immune Response and Overcoming Resistance (Ballroom C) - Apr 24, 2022 - Abstract #PEGS2022PEGS_499;
We will report the discovery and preclinical studies of EPIM-001, a bispecific IL2/PD-L1 biologics that has demonstrated multiple mechanisms of action and potent anti-tumor activity; EPB-001, a human anti-Siglec15 antibody that reversed immune suppression and inhibited tumor growth. EPIM-001 and EPB-001 could be promising therapeutics for tumors that are non-responding or resistant to immune checkpoint inhibitor treatment.
- |||||||||| EPIM-001 / Elpis Biopharma
Discovery of EPIM-001, a tumor targeted engineered IL2 with biased IL2Rβ agonist activities (Section 18) - Mar 9, 2022 - Abstract #AACR2022AACR_2487;
Furthermore, in the human breast cancer cell line MDA-MB-231, EPIM-001 showed stronger tumor growth inhibition compared to Keytruda. EPIM-001 is a promising immune modulating drug candidate that selectively activates CD8+ T cells and NK Cells with strong anti-tumor activity and safe profile for both immune checkpoint sensitive and insensitive PD-L1 positive tumors.
|
